Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo oral solution Clear all
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401
View directory record Official record
Conditions
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
Interventions
AP01, Placebo
Drug · Other
Lead sponsor
Avalyn Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
61
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 25, 2026, 4:35 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease

NCT04311112
View directory record Official record
Conditions
Retinal Disorder
Interventions
Placebos, ZA Low dose, ZA high dose
Drug
Lead sponsor
Retinagenix Holdings
Industry
Eligibility
6 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers

NCT01907776
View directory record Official record
Conditions
Healthy
Interventions
ME1100 inhalation solution, ME1100 placebo inhalation solution
Drug
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Sep 25, 2026, 4:35 PM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
Clemizole HCl, Placebo
Drug
Lead sponsor
Epygenix
Industry
Eligibility
2 Years to 55 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Little Rock, Arkansas • Orange, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 4:35 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Lesion Progression After Icon Treatment in Young Adults

NCT01988337
View directory record Official record
Conditions
Caries, Salivary Function, Tooth Sensitivity
Interventions
Resin infiltration, Mock treatment
Device · Other
Lead sponsor
DMG Dental Material Gesellschaft mbH
Industry
Eligibility
19 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 25, 2026, 4:35 PM EDT
Terminated Phase 4 Interventional Results available

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

NCT01100437
View directory record Official record
Conditions
Chronic Pain
Interventions
EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human Study Of Increasing Oral Doses Of PF-04634817

NCT01098877
View directory record Official record
Conditions
Healthy
Interventions
PF-04634817 Placebo, PF-04634817
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 25, 2026, 4:35 PM EDT
Withdrawn Phase 1 Interventional

Sirolimus in COVID-19 Phase 1

NCT04371640
View directory record Official record
Conditions
SARS-CoV-2, Covid-19
Interventions
Sirolimus 1 MG/ML, Placebo
Drug
Lead sponsor
Walter K. Kraft
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia

NCT01769274
View directory record Official record
Conditions
Inherited Erythromelalgia
Interventions
PF-05089771, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 78 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

BCAA Supplementation for Concussion

NCT01860404
View directory record Official record
Conditions
Brain Concussion
Interventions
Branched Chain Amino Acids, Placebo solution
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
11 Years to 34 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

NCT02066909
View directory record Official record
Conditions
Healthy
Interventions
0.15 mg PF-06649751, 0.5 mg PF-06649751, 1.5 mg PF-06649751, 1.5 mg PF-06649751 21 Days, 3.0 mg PF-06649751, 5.0 mg PF-06649751, 8.0 mg PF-06649751, 1.5 mg PF-06649751 in healthy Japanese subjects
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00643201
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 1 Interventional

18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia

NCT06880328
View directory record Official record
Conditions
Schizophrenia
Interventions
Ralmitaront, Radiolabeled PET tracer [18F]-DOPA, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Glendale, California • Torrance, California • Gaithersburg, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT02205528
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus Type 2
Interventions
Liraglutide, Metformin, Placebo, NNC0090-2746
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

NCT00044707
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional

BLI801 Laxative in Constipated Adults

NCT01301781
View directory record Official record
Conditions
Constipation
Interventions
BLI801, Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
4
States / cities
Anaheim, California • Jupiter, Florida • New Smyrna Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabidiol Effects on Blood Alcohol Level and Intoxication

NCT06105138
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
200mg Cannabidiol oral solution, 30mg Cannabidiol oral solution, Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
21 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

NCT03201419
View directory record Official record
Conditions
Nocturia
Interventions
FE 201836, Desmopressin, Placebo oral solution, Placebo ODT
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Lincoln, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

NCT04208412
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900, Placebo
Drug · Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Scottsdale, Arizona • Centennial, Colorado • Chevy Chase, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Rilpivirine, Placebo
Drug
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Newark, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Sep 25, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia

NCT00371137
View directory record Official record
Conditions
Fibromyalgia
Interventions
Xyrem®, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
70
States / cities
Anniston, Alabama • Huntsville, Alabama • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Sep 25, 2026, 4:35 PM EDT
Recruiting Phase 3 Interventional

Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder

NCT07123467
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Anxiety Disorders
Interventions
Low-Dose Cannabidiol, Placebo Matched to Moderate-Dose Cannabidiol, Moderate-Dose Cannabidiol, Placebo Matched to Low-Dose Cannabidiol
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 25, 2026, 4:35 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

NCT05846399
View directory record Official record
Conditions
Cat Bite, Hand Injuries, Arm Injury, Infection, Bacterial, Anti-bacterial Agents
Interventions
Amoxicillin/clavulanate, Ciprofloxacin, Clindamycin, Placebo (microcrystalline cellulose), Wound management
Drug · Other · Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 25, 2026, 4:35 PM EDT